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D-penicillamine and sodium salicylate were equally 
effective in suppressing the proliferation of fibroblasts 
from normal and scleroderma skin and rheumatoid syn-
ovial cells. The effects were concentration-dependent, 
beginning at around 100 ,ug/ml, and proliferation was 
almost halted at 1600 ,ug/ml. Individual cell strains of 
each type showed differences in drug susceptibility but 
there was no consistent difference between cells from 
normal and abnormal tissues. 
Acid mucopolysaccharide secretion was more clearly 
inhibited in scleroderma fibroblasts than in synovial 
cells, and penicillamine produced greater inhibition than 
salicylate, beginning at 10 ~-tg/ml and reaching almost 
50% at 500 ,ug/ml. Confluent cultures of scleroderma 
fibroblasts showed 23% less incorporation of 3H-proline 
into collagenase-sensitive protein in the presence of 1600 
p.g/ml penicillamine, without significant effect on other 
protein synthesis; sodium salicylate had no effect. These 
data suggest that D-penicillamine may affect connective 
tissue metabolism in other ways than by interfering with 
collagen synthesis or cross-linking. 
There is still no satisfactory treatment for scleroderma (sys-
temic sclerosis) but some patients benefit from D -penicillamine; 
the same drug is finding increasing use in rheumatoid arthritis 
although the mechanism of its antirheumatic action is un-
known. Penicillamine is a highly reactive compound with many 
different properties [1], but in scleroderma its main action 
appears to be to interfere in collagen metabolism, especially, or 
perhaps exclusively, in the skin. Some aspects of this effect are 
now well established: cross-linking of collagen is blocked 
through thiazolidine ring formation with peptide-bound alde-
hyde groups, and newly formed aldimine cross-links are cleaved, 
the end result being a greater proportion of soluble collagen [2-
4]. If scleroderma involves increased collagen synthesis [5-8], 
reduction of the rate of collagen peptide synthesis is also a 
desirable therapeutic action. Perlish et al [9], whose cell culture 
studies showed no excessive collagen synthesis by scleroderma 
fibroblasts (cf [6,8]) , suggested that scleroderma may involve 
increased proliferation of fibroblasts, so that the total collagen 
synthesis increases through the presence of more secretory 
cells. Many antiinflammatory and antirheumatic drugs, like 
salicylates, can control fibroblast proliferation, acid mucopoly-
saccharide secretion and synthesis of proteins in vitro [10,11] 
and, to varying degrees, in vivo. We therefore tested penicillam-
ine's ability to influence these 3 parameters, and made similar 
tests with sodium salicylate, using fibroblasts from normal and 
scleroderma skin and cells cultured from rheumatoid synovia. 
ORIGIN AND CULTURE OF CELLS 
Normal infant foreskin fibroblasts, designated strains HSF3-
6, and also adult forearm fibroblasts (strain HSF8) were ob-
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tained from the Royal Hospital for Sick Children, Edinburgh. 
The rheumatoid synovial cell strains RA1-6 and scleroderma 
fibroblasts SD3-10 were those isolated for tests on other drugs 
[12,13] so that results could be compared. The rheumatoid 
synovial cell strains were isolated from tissue removed at knee 
or elbow synovectomy of rheumatoid arthritis patients (average 
age 60), as previously described [12]. In the scleroderma group, 
strains SD3 and SD6 were derived from patients with systemic 
sclerosis attending this Department [ 12]; 2 further strains (SD9: 
generalized morphoea, age 50; SD10: systemic sclerosis, age 56) 
were kindly provided by Dr F.M. Pope; all biopsies were from 
the upper arm. Normal cells were used in passages 11-22, 
scleroderma strains in passages 10-18 and synovial cells in 
passages 6-12. 
Cells were maintained in Nunc plastic flasks in Dulbecco-
Eagle medium with 10% fetal calf serum, 100 units/ ml penicillin, 
100 J.Lg/ ml streptomycin and 4 mM glutamine (all from Gibco-
Biocult, Ltd. Paisley) at 37°C, as previously described [14]. The 
medium was replaced 3 times weekly. Cells were harvested with 
trypsin-versene and counted electronically (Coulter Counter 
Model DN). 
PROLIFERATION TESTS 
Four cell strains were tested in each group. (In the normal 
fibroblast group HSF8 cells were reserved for the additional 
experiments described later.) Separate experiments were per-
formed for the 2 drugs. On day 0 twenty-four flasks (25 cm2 
growth area) were seeded with aliquots of about 1 x 105 cells. 
On day 1 the medium was changed. On day 3 four flasks were 
withdrawn for cell counts, while the rest were grouped in 4's to 
receive medium containing 4 different concentrations of either 
sodium salicylate (16, 160, 640, 1600 J.Lg/ ml) or D-penicillamine 
hydrochloride (10, 50, 100, 500 J.Lg/ ml) with a second control 
g:roup of 4 flasks. All media were renewed on day 4 and on day 
6 cell numbers were counted in all flasks. The increase in cell 
number in media containing drugs was expressed as a percent-
age of the increase in controls between days 3 and 6. Final cell 
numbers were about 1 X 106 fibroblasts and 0.7 X 106 synovial 
cells. To test the effect of higher concentrations of D-penicil-
lamine but avoid the depression of pH caused by the hydro-
chloride 3 extra experiments were pelformed with D-penicil-
lamine free base at concentrations of 50, 100, 500, and 1500 !Lgl 
ml. A recovery experiment was performed to assess cytotoxicity. 
Proliferation between days 3 and 6 was measured as usual in 
cultures of HSF8 fibroblasts exposed to 1600 J.Lg/ ml of salicylate 
or penicillamine free base, and viability counts were made on 
the cell suspensions obtained on day 6 using 0.5% nigrosin. Two 
other sets of cultures were allowed to recover from drug treat-
ment: on day 6 the drug media were replaced with fresh 
medium, which was again changed on day 8, and the cells were 
counted on day 10. 
ACID MUCOPOLYSACCHARIDE SECRETION 
Medium added on day 4 and collected on day 6 of prolifera-
tion experiments and 1 ml of phosphate buffered saline used to 
rinse the cell layers was assayed for uronic acid with a metah-
ydroxydiphenyl reagent [15] after dialysis and elimination of 
protein as previously described [12,14]. Four rheumatoid strains 
and 2 scleroderma strains were tested. Uronic acid output per 
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culture was determined by subtracting the uronic acid content 
of each batch of medium (assayed along with experimental 
samples) and output per 107 cells was calculated from the day 
6 cell counts. The outputs of the 6 cell strains ranged from 60 
to 167 llg uronic acid per 107 cells. 
COLLAGEN SYNTHESIS 
Protein synthesis was assessed in confluent cultures of SD3, 
SD6 and SD9 fibroblasts grown in plastic multiwell dishes in 
medium containing 50 fJ.g/ml ascorbic acid. Total protein syn-
thesis was monitored as incorporation of 3H-proline and colla-
gen synthesis as incorporation of ·'H-proline over 24 hr into 
collagenase-sensitive protein. D-penicillamine was tested at 50-
1600 Jlg/ ml. using the free base for the 500, 1000 and 1600 fJ.g 
concentrations, and sodium salicylate at 100-1600 fJ.g / ml. 
Each experiment compared 3 treatments-either control and 
2 concentrations of the same drug, or control and both drugs at 
the same concentration. Two of the 3 treatments were com-
pared in each 6-well dish; 3 wells were allocated to a treatment 
and their material subsequently pooled to give a single prepa-
ration. Each experiment compared 5 preparations for each 
treatment. For the incubation each well received 1 ml of me-
dium (without antibiotics or serum) containing 10 J.tCi (5-H3) 
proline (Radiochemical Centre, Amersham) with or without 
the appropriate concentration of drug, and the dishes were then 
incubated at · 37° for 24 hr in a 5% C02/95% air atmosphere. 
The cultures were then cooled to 4°C and the medium with-
drawn. To the medium was added 1 ml of phosphate buffered 
saline used to rinse the cells, which were next allowed to swell 
in 1 ml distilled water for 30 min, then removed from the dishes 
with a jet of distilled water and passed through a fine hypoder-
mic needle several times, which effectively homogenized them. 
Carrier protein (1 drop 1% serum albumin) was added to each 
sample and then trichloracetic acid (TCA) to a final concentra-
tion of 5%. Protein precipitates were collected by centrifugation 
at 2000 rpm (4°C) and washed successively with ethanol con-
taining 2% sodium acetate, ethanol-ether (3:1) and ether. The 
dry pellets were redissolved in 0.5 rnl 0.2 N KOH, neutralized 
with 0.2 rnl 0.4 N HCl and diluted with 2 ml Tris-HCl buffer pH 
7.6 containing 10 mM calcium chloride for division into 2 ali-
quots. One aliquot was incubated with 100 units of collagenase 
(Advance Biofactures Corp. Lynbrook, New York) overnight at 
37°, while the othey aliquot was incubated with buffer. Protein 
was then reprecipitated in cold 5% TCA containing 0.25% tannic 
acid, washed as before and dried. Residues were dissolved in 
hyamine hydroxide, acidified with glacial acid and added to 10 
rnl NE233 scintillation mixture (Nuclear Enterprises, Edin-
burgh, Scotland) for liquid scintillation counting. A quench 
correction by external standard channels ratio was used to 
convert cpm to dpm. 
As collagenase from this source is substantially free from 
proteases [16,17] all radioactivity dispersed by the enzyme was 
regarded as collagen. The proportion of the total protein-bound 
radioactivity present in the medium as opposed to in the cell 
layer was expressed as percentage secretion. Relative collagen 
synthesis, the proportion of total protein synthesis which is 
collagen, was calculated by the method of Diegelmann and 
Peterkofsky [18]. 
RESULTS 
Cell Proliferation 
The effects of the 2 drugs on cell proliferation are summarized 
in Fig 1. Representation of each group of 4 cell strains as a 
single curve conceals several differences between the individual 
strains within a group. This is illustrated for salicylate in the 
scleroderma group in Fig 2; the 4 normal strains showed about 
the same degree of agreement, · while the 4 synovial strains 
agreed rather better than the ·scleroderma group. Fig 1 shows 
that sodium salicylate produced dose-related inhibition of pro-
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FIG 1. Effect of D-penicil lamine hydrochloride (e) and sodium sa-
licylate (0 ) on the proliferation of normal (HSF- - - - - - -) and 
scleroderma (SD . .... ) skin fibroblasts, and rheumatoid synovial cells 
(RA---). Each point is a mean representing 4 cul tures of each of 4 
cell strains (n = 16). Proliferation of controls over days 3- 6 was 
represented as 100, and drug-treated cultures as a proportion of that. 
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FIG 2. Effect of sodium salicylate on individual strains of sclero-
derma fibroblasts (averaged together in Fig 1) . Each point is a mean 
from 4 cultures (± SE) ; standard errors of controls ranged from ± 3 in 
SD9 to ± 8 in SD6. 
liferation beginning at between 100 and 200 flg/ml . At 1600 Jlg / 
ml proliferation was reduced to about 10-20% of that in controls, 
and the curves suggest that it would be completely halted at 
just over 2000 Jlg/ rnl. The overall sensitivities of the 3 cell 
groups were fairly similar: mean IDr,o values read from regres-
sion lines calculated for all the 160, 640, and 1600 J.tg/ rnl data in 
each group were 457 (HSF), 501 (RA) and 562 (SD) fJ.g / ml. 
With penicillamine hydTochloride there was significant inhib-
tion at 100 fJ.g/ml in only a few cell strains, but 30-40% inhibition 
at 500 fJ.g/rnl, with no significant difference between the 3 
groups of cell strains at this concentration (Fig 1) . Although 
this suggested that penicillamine was slightly less potent that 
sodium salicylate, replotting the results as penicillamine itself 
(500 fJ.g hydrochloride contains 400 llg penicillamine) would 
reduce the discrepancy. Furthermore, the 3 experiments with 
penicillamine free base at 500, 1000 and 1500 fJ.g/ ml, using 
HSF8, SD9 and RA1 cells gave results (Fig 3) which fall within 
the range of salicylate effects. This shows that flg for llg the 2 
drugs are equally potent in suppressing proliferation. 
Morphological changes in cells treated with the highest con-
centrations of the 2 drugs, where proliferation was inhibited by 
85-95%, were limited to slight contraction of the cell margins 
and scarcity of mitoses. There was no sign of cells detaching 
from the flasks. In the recovery experiment cell viability was 
85- 86% in both treated and control cell suspensions counted on 
day 6. Normal appearance and mitosis were resumed 24 hr after 
returning cultures to drug-free medium and by day 10 cell 
numbers had recovered to 58% (after salicylate) and 67% (after 
penicillamine) of those recorded in day 6 contmls. Both drugs 
were therefore cytostatic but not cytotoxic in the range of 
concentrations used in these experiments. 
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Acid Mucopolysaccharide Secretion 
Both drugs inhibited acid mucopolysaccharide secretion (Fig 
4) but the effect was clearer and more obviously dose-related in 
scleroderma fibroblasts than in the rheumatoid synovial cells, 
and within each cell- type penicillamine hydrochloride was more 
potent than the same concentrations of salicylate. In the 2 
scleroderma strains the inhibition with penicillamine appeared 
to begin at 10 llg/ ml, and reached almost 50% at 500 !-(g/ml (r 
- 0.72, p < 0.001 at 36 degrees of freedom) ; salicylate was 
inhibitory from about 50-100 !lg!ml and gave 42% suppression 
at 1600 !lglml (r - 0.81, p < 0.001 at 29 dt) . In the rheumatoid 
synovial cells there was only about 20% inhibition with 500 llg/ 
ml penicillamine hydrochloride and 1600 !-(g/ ml salicylate. All 
these effects are calculated on the basis of a constant number 
of cells: they are additional to reduction in total secretion where 
proliferation was suppressed and fewer cells were present. 
Penicillamine (free base) P.g ( ml 
FIG 3. Effect of penicillamine (free base) on t he proliferation of 
HSF8, RA1 and SD9 cells. Each point is a mean from 4 cultures± SE. 
Standard errors of controls were± 2 (RA1 and SD9) and ± 6 (HSF 8). 
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FIG 4. Effect of penicillamine hydrochloride and sodium salicylate 
on acid mucopolysaccharide secretion by 2 strains of scleroderma 
fibroblasts (SD3 and SD6, n = 8) , and 4 strains of rheumatoid synovial 
cells (RA, n = 16). The ba.rs indicate standard errors. 
Protein Synthesis 
Neither <hug affected total protein synthesis at low doses 
(Table I) . A suggestive decrease of about 20% in collagen 
synthesis with 100 llg/ ml salicylate in SD3 cells was not con-
firmed at 200 llg/ ml and was not seen in SD6 cells. At 1000 !lgl 
ml (Table II) penicillamine treated cultures contained 20% less 
collagen protein than controls (p = 0.1) and at 1600 llg/ml 
penicillamine showed 23% depression of collagen synthesis (p 
< 0.05) without a corresponding effect on other protein. The 
data also suggest that at 1000 and 1600 llg/ ml penicillamine 
may affect secretion of collagen and other protein, but the 
differences from controls were not statistically significant. 
DISCUSSION 
A criticism sometimes made of this type of pharmacological 
study is that any inhibitory effects may reflect a general toxicity 
brought about by the drug used. Such a charge does not fit the 
results recorded here, since at the highest concentration used 
total protein synthesis was unaffected, cell viability was normal 
even after 3 days, and the cells were able to resume DNA 
synthesis and proliferate when released from inhibition by 
withdrawal of the drugs. Both drugs were th erefore having a 
cytostatic rather than a cytotoxic action, and only certain 
aspects of their metabolism were affected. The finding t hat acid 
mucopolysaccharide secretion is more sensitive to inhibition by 
salicylate than cell proliferation, which is in turn more sensitive 
than protein synthesis agrees with earlier work [10], and is 
further evidence of the selective nature of the drug action. 
Experience of D-penicillamine in the treatment of sclero-
derma and other collagen diseases has been mixed. There are 
enthusiastic reports that all cutaneous manifestations o( sys-
temic sclerosis, morphoea and keloids a1·e completely resolved 
[19], records of more qualified successes with systemic sclerosis 
[20] and some groups of systemic sclerosis patients for whom 
penicillamine brings little benefit [21]. Penicillamine's interfer-
ence with collagen cross-linking is now beyond doubt but we 
have not encountered the big reduction in the rate of amino 
acid incorporation into collagen peptide reported by Ditto [8] 
at relatively low penicillamine concentrations in experiments 
with mouse embryos, and by Herbert et al [ 4] who studied 
scleroderma skin, both groups using organ cultures. In this 
respect our results support the conclusions [2,22,23] that (at 
pharmacological concentrations) penicillamine does not affect 
t~e ra.te ~f collagen synthesis. Clinical experience that only skin 
f1bros1s IS affected by penicillamine in systemic sclerosis 
[ 4,19,20] sugges~s cross-linking of collagen rather than synthesis 
of collagen ?ept1de as the main target for the drug, t he selective 
effect relatmg to the distribution of penicillamine-labile aldi-
~i~e. c.ross-links in skin but not in other sites [ 4]; prolonged 
~nhlbitlon of c?llagen syn thesis would probably deplete collagen 
m all connective ttssues. 
Our data suggest t hat some contribution to penicillamine's 
TABLE I. Effects of D·penicillamine and sodium salicylate on protein synthesis by scleroderma fibroblasts 
Relative 
Cells Tolal collagen Drug l'g/ ml Total other collagen dpm dpm synthesis 1' 
% 
SD3 P en 0 94554 194590 8.3 
50 83502 202431 7.1 
100 106270 212106 8.5 
SD6 and SD9 strains showed similar lack of effect. Relative collagen synthesis - 4 
SD3 Sal 0 104848 202018 8.8 
100 79022" 196338 7.0 
200 84681 198879 7.3 
SD6 and SD9 strains showed no significant effect. Relative collagen synthesis _ 3 
" Calculated according to Diegelmarm & Peterkofsky [18). 
" p < 0.05 Wilcoxon test. n = 5. 
%Collagen % Other protein secreLed secreted 
85 36 
84 38 
86 36 
6%" 
85 38 
93 34 
88 36 
5%" 
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TABLE II. Effect of D·penicillamine and sodium salicylate at high 
concentration on protein synthesis by SD9 scleroderma fibroblasts 
Total Total Relative % %Other 
Drug Jig/ml collagen other collagen Collagen protein 
dpm dpm synthesis secreted secreted % 
Control 35875 165263 3.9 92 21 
Sal500 41663 157717 4.7 82 26 
Pen 500 42471 142460 5.3 84 22 
Control 51070 193272 4.9 82 16 
SallOOO 46545 190721 4.3 76 20 
Pen 1000 40378 194452 3.8 60 14 
Control 44554 157980 5.0 81 21 
Sall600 35005 155683 4.1 82 24 
Pen 1600 34122" 141268 4.4 66 13 
" l-test p < 0.05 n = 5. 
action in connective tissue could arise through control of the 
number of fibroblasts available to secrete collagen (and other 
macromolecules) and through suppression of acid mucopoly-
saccharide secretion by individual fibroblasts, actions charac-
teristic of anti-inflammatory and antirheumatic drugs, including 
salicylates [10,11]. There have been other suggestions of these 
actions of penicillamine recently in rat and mouse cell cultures 
[24,25]. If scleroderma involves excessive fibroblast prolifera-
tion [9] rather than higher collagen output per fibroblast 
[6,8,26,27] then pharmacological limitation of fibroblast num-
bers is clearly desirable. Lower secretion of acid mucopolysac-
charides, constituents with short half-lives [28], will quickly 
reduce hyaluronic acid concentration and the water-binding 
capacity of the tissue, the end result of which would be to 
reduce oedema, a feature of both scleroderma skin and the 
rheumatoid joint. 
These 2 actions of D-penicillamine in vitro would therefore 
be clinically useful; but the question of concentration is all 
important. Taking 15 llg/ml as a likely concentration of peni-
cillamine in plasma [29] the data in this study show some 
depression of acid mucopolysaccharide secretion in vitro at this 
point, but cell proliferation proceeds unaffected in most strains 
until about 150 llg/rnl, so restriction of this activity by penicil-
lamine in vivo is less likely. Much the same reasoning applies 
to sodium salicylate, where these actions are well known, but 
the higher concentration attainable (300 or even 400 llg salicy-
late per rnl plasma) make control of both acid mucopolysaccha-
ride secretion and cell proliferation in vivo quite plausible. Such 
argument assumes equal potency in vivo and in vitro for each 
drug, but this may not be the case; Uitto et al [30] found that 
in chick embryos much higher corticosteroid concentrations 
were needed to depress collagen synthesis in vitro than in vivo. 
A similar differential susceptibility to penicillamine would make 
the effects on cell proliferation and mucopolysaccharide syn-
thesis more likely to occur in patients receiving the drug. 
The majority of reports [6,8,26,27] now agree in showing 
excessive collagen synthesis by scleroderma fibroblasts, al-
though Perlish et al [9] found activity equal to, or less than, 
that of normal cells. An infrequent or "suboptimal" feeding 
schedule has been regarded as crucial in the expression of the 
scleroderma phenotype [26,27] but others [8] produced com-
parable results with a conventional schedule similar to that 
followed in the present work. We have not attempted to com-
pare collagen synthesis by normal and scleroderma fibroblasts, 
such a comparison being invalid except where cells are strictly 
matched for site, and age and sex of donor. In fact the 3 
scleroderma strains used to study effects on collagen synthesis 
were somewhat dissimilar. In SD6 and SD9 collagen was within 
the range 3-6% of total protein synthesis (relative collagen 
synthesis in Tables I and II) seen in normal fibroblasts 
[6,12,14,31] but in SD3 cells collagen reached 7-8%, significantly 
higher than in the other two strains (p < 0.001), within the 
range quoted for scleroderma cells [26], and close to that for 
keloid fibroblasts [31]. Yet in some earlier experiments [12] 
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SD3 cells at only slightly earlier passage gave more "normal" 
values; the reason for the change is not known, although others 
have reported increases in the rate of macromolecule synthesis 
in later passage fibroblasts [32]. Relative collagen synthesis in 
SD3 apart, no changes in the performance of the fibroblasts, or 
their response to the 2 drugs, was seen in relation to passage 
number, and no differences attributable to site or age of donor 
(i.e., comparing HSF3-6 infant foreskin cells with HSF8 from 
adult forearm) were noted. Unfortunately the very large num-
bers of cells required for these and other concurrent drug tests 
[12-14,33], and for storage of the same cell lines in liquid 
nitrogen as insurance against loss, prevented experimentation 
on cells at lower passage. Differences in scleroderma fibroblast 
strains in collagen synthesis and other characteristics [13] may 
relate to the site of the biopsy within the lesion or the state of 
activity of the patient's disease; they make it important that 
several strains are used in tests of drug response. 
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Announcement 
The 3rd Annual Postgraduate Course and Workshop in Medical Mycology (Dermatomycology) will be 
held September 15-17, 1980, at the University of California, San Francisco, California. 
The course in dermatomycology is being offered for dermatologists, clinical pathologists, medical 
mycologists, and other persons interested in the current status of medical mycology. For further 
information please contact Extended Programs in Medical Education; Room U-569, University of 
California, San Francisco, CA 94143 or call (415) 666-4251. 
